Pharnext SA

Pharnext SA is reeling after the failure of its only late-stage asset PXT3003 less than a month after claiming that three companies were vying to partner the potential therapy for Charcot-Marie-Tooth

Janux Therapeutics brought the number of biopharmaceutical initial public offerings in the US this year to 47 when it priced an IPO of 11.4 million shares at $17 each on 11 June to gross $193.8m. The

David Horn Solomon joined Pharnext SA , a clinical-stage biopharmaceutical company that is developing new drug combinations based on big genomic data and artificial intelligence, in April 2020. He to

"The coming year will be remembered for the epic alteration to our society." These words from Pam Contag , CEO and co-founder of BioEclipse Therapeutics, Inc. , encapsulate the enormity of COVID-19'